SCHEMBL1744650

SCHEMBL1744650

CCCN(Cc1ccc(COc2ccc(CCC(=O)O)c(C)c2)cc1)c1nc(-c2ccccc2)cs1

nearest known ligand 0.57

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 8/20 0.57
FFAR1 O14842 8/20 0.50
PPARA Q07869 3/20 0.45
PPARG P37231 2/20 0.44
FFAR4 Q5NUL3 2/20 0.43
KMT2A Q03164 4/20 0.42
MEN1 O00255 3/20 0.42
NPSR1 Q6W5P4 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MAPT P10636 1/20 0.42
HTT P42858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1745729 0.93 PPARD (0.49) PPARDFFAR1PPARAKMT2AMEN1
SCHEMBL1745640 0.93 FFAR1 (0.50) PPARDFFAR1FFAR4
SCHEMBL1745053 0.90 FFAR1 (0.53) PPARDFFAR1PPARAPPARGFFAR4
SCHEMBL3921201 0.86 FFAR1 (0.51) PPARDFFAR1FFAR4KMT2AMEN1
SCHEMBL1746741 0.86 FFAR1 (0.42) PPARDFFAR1PPARAPPARGFFAR4
SCHEMBL3917963 0.84 PPARD (0.49) PPARDFFAR1PPARAPPARGFFAR4
SCHEMBL3912223 0.83 PPARD (0.57) PPARDFFAR1PPARAPPARGFFAR4
SCHEMBL1746715 0.83 PPARD (0.53) PPARDFFAR1PPARAPPARGFFAR4
SCHEMBL1996575 0.83 PPARD (0.53) PPARDFFAR1NPSR1
SCHEMBL3921961 0.83 PPARD (0.54) PPARDFFAR1PPARAPPARGFFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR PPARD 326/4885FFAR1 33/4885PPARA 397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.